Replimune Group Files 8-K on Financials
Ticker: REPL · Form: 8-K · Filed: 2025-02-12T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, operations, filing
TL;DR
Replimune Group dropped an 8-K detailing their financial condition and operations as of Feb 12, 2025.
AI Summary
Replimune Group, Inc. filed an 8-K on February 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 500 Unicorn Park Drive, Woburn, MA.
Why It Matters
This filing provides investors with crucial updates on Replimune Group's financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any immediate negative news or significant changes.
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant
- February 12, 2025 (date) — Date of earliest event reported
- 500 Unicorn Park Drive Suite 303 Woburn , MA 01801 (address) — Principal executive offices
- ( 781 ) 222-9600 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated February 12, 2025.
Where are Replimune Group, Inc.'s principal executive offices located?
The principal executive offices are located at 500 Unicorn Park Drive Suite 303 Woburn, MA 01801.
What is the company's telephone number?
The company's telephone number is (781) 222-9600.
What is the SIC code for Replimune Group, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-02-12 08:06:00
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
Filing Documents
- tm256243d1_8k.htm (8-K) — 26KB
- tm256243d1_ex99-1.htm (EX-99.1) — 63KB
- 0001104659-25-011851.txt ( ) — 266KB
- repl-20250212.xsd (EX-101.SCH) — 3KB
- repl-20250212_lab.xml (EX-101.LAB) — 33KB
- repl-20250212_pre.xml (EX-101.PRE) — 22KB
- tm256243d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 12, 2025, Replimune Group, Inc. (the "Company") issued a news release announcing its financial results for the fiscal quarter ended December 31, 2024 and certain corporate updates. A copy of the news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 News Release dated February 12, 2025 104 Cover page interactive data file (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: February 12, 2025 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer